{'fraction_non_alphanumeric': 0.02890932982917214, 'fraction_numerical': 0.017082785808147174, 'mean_word_length': 5.096, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
This Month's Highlights.

Profibrotic Effects of SREBP-1 The transcription factor SREBP-1 has been shown to induce glomerular sclerosis and is activated by angiotensin II in tubular cells. Wang et al. examined whether SREBP-1 mediates the profibrotic effects of angiotensin II in mesangial cells. In vitro, activation of SREBP-1 by angiotensin II stimulates TGF-b upregulation and fibronectin synthesis in a manner that requires endoplasmic reticulum stress and activation of Akt. In mice, administration of an SREBP-1 inhibitor attenuates angiotensin II-induced upregulation of TGF-b signaling and matrix accumulation. These results suggest novel therapeutic targets that should be explored for the treatment of renalfibrosis. See Wang et al., pages 1839–1854.